Drug Profile
Research programme: radiopharmaceuticals - Precirix
Latest Information Update: 05 May 2021
Price :
$50
*
At a glance
- Originator Camel-IDS
- Developer Precirix
- Class Antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for research development in Cancer in Belgium
- 16 May 2016 Early research in Cancer in Belgium (unspecified route)